株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

術後疼痛:パイプライン製品の分析

Post-Operative Pain - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 227536
出版日 ページ情報 英文 187 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
術後疼痛:パイプライン製品の分析 Post-Operative Pain - Pipeline Review, H1 2017
出版日: 2017年02月28日 ページ情報: 英文 187 Pages
概要

疼痛は、術後の患者にストレスを感じさせる主な有害事象の一つです。疾病素質には年齢や、恐怖・不安のレベル、外科手術工程、個人的な選考、投与された薬剤への反応などが挙げられます。主な治療薬には、鎮痛剤や麻酔薬などがあります。

当レポートでは、世界各国での術後疼痛治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

術後疼痛の概要

治療薬の開発

  • 術後疼痛向けパイプライン製品:概要
  • 術後疼痛向けパイプライン製品:比較分析

各企業で開発中の術後疼痛治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

術後疼痛治療薬:開発中の製品の一覧(企業別)

術後疼痛治療薬の開発に従事している企業

  • AcelRx Pharmaceuticals, Inc.
  • Adynxx, Inc.
  • AngioChem Inc.
  • AskAt Inc.
  • Boehringer Ingelheim GmbH
  • Cara Therapeutics, Inc.
  • Colby Pharmaceutical Company
  • Cytogel Pharma, LLC
  • Dompe Farmaceutici S.p.A.
  • DURECT Corporation
  • Echo Pharmaceuticals B.V.
  • 藤本製薬
  • Galleon Pharmaceuticals
  • Grunenthal GmbH
  • GW Pharmaceuticals Plc
  • Heron Therapeutics, Inc.
  • Immupharma Plc
  • Innocoll AG
  • INSYS Therapeutics, Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lipocure Ltd.
  • Liquidia Technologies, Inc.
  • Medtronic plc
  • Orbis Biosciences, Inc.
  • Orion Oyj
  • Pacira Pharmaceuticals, Inc.
  • PainReform Ltd.
  • Pharmazz, Inc.
  • PhytoHealth Corporation
  • Proteus SA
  • Recro Pharma, Inc.
  • Relmada Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SteadyMed Therapeutics, Inc.
  • 武田薬品工業
  • The Medicines Company
  • Trevena, Inc.

術後疼痛:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

術後疼痛治療薬:開発が休止状態の製品

術後疼痛治療薬:開発が中止された製品

術後疼痛関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8951IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Pipeline Review, H1 2017, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 9, 16, 10, 13, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post-Operative Pain - Overview
  • Post-Operative Pain - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Post-Operative Pain - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Post-Operative Pain - Companies Involved in Therapeutics Development
    • AcelRx Pharmaceuticals Inc
    • Adynxx Inc
    • AngioChem Inc
    • Aoxing Pharmaceutical Company Inc
    • AskAt Inc
    • Boehringer Ingelheim GmbH
    • Camurus AB
    • Cara Therapeutics Inc
    • Colby Pharmaceutical Company
    • Cytogel Pharma LLC
    • Dompe Farmaceutici SpA
    • DURECT Corp
    • Eupraxia Pharmaceuticals Inc
    • EyeGate Pharmaceuticals Inc
    • Fujimoto Pharmaceutical Corp
    • Grunenthal GmbH
    • GW Pharmaceuticals Plc
    • Heron Therapeutics Inc
    • Immupharma Plc
    • Innocoll AG
    • INSYS Therapeutics Inc
    • iX Biopharma Ltd
    • Laboratorios Del Dr Esteve SA
    • Lipocure Ltd
    • Liquidia Technologies Inc
    • Medtronic Plc
    • Novartis AG
    • Orbis Biosciences Inc
    • Orion Oyj
    • Pacira Pharmaceuticals Inc
    • PainReform Ltd
    • Pharmazz Inc
    • PhytoHealth Corp
    • PixarBio Corp
    • Proteus SA
    • Recro Pharma Inc
    • Relmada Therapeutics Inc
    • Serina Therapeutics Inc
    • SteadyMed Therapeutics Inc
    • Teikoku Pharma USA Inc
    • The Medicines Company
    • Trevena Inc
  • Post-Operative Pain - Drug Profiles
    • (bupivacaine hydrochloride + meloxicam) ER - Drug Profile
    • (buprenorphine hydrochloride + granisetron hydrochloride) ER - Drug Profile
    • A-100 - Drug Profile
    • ANG-2002 - Drug Profile
    • ARX-04 - Drug Profile
    • AYX-1 - Drug Profile
    • BI-1026706 - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride SR - Drug Profile
    • bupivacaine hydrochloride SR - Drug Profile
    • buprenorphine hydrochloride - Drug Profile
    • CAM-2048 - Drug Profile
    • carbamazepine - Drug Profile
    • CPC-111 - Drug Profile
    • CPC-123 - Drug Profile
    • Cyt-1010 - Drug Profile
    • dexamethasone acetate - Drug Profile
    • dexmedetomidine hydrochloride - Drug Profile
    • DF-2755A - Drug Profile
    • difelikefalin - Drug Profile
    • ECP-1014 - Drug Profile
    • fadolmidine hydrochloride - Drug Profile
    • fentanyl - Drug Profile
    • gonyautoxin - Drug Profile
    • grapiprant - Drug Profile
    • HTX-009 - Drug Profile
    • HYLP-002 - Drug Profile
    • IPP-102199 - Drug Profile
    • ketamine hydrochloride - Drug Profile
    • ketorolac tromethamine - Drug Profile
    • lacosamide - Drug Profile
    • levorphanol tartrate ER - Drug Profile
    • MDT-10013 - Drug Profile
    • meloxicam - Drug Profile
    • meloxicam ER - Drug Profile
    • MR-309 - Drug Profile
    • nabiximols - Drug Profile
    • nalbuphine hydrochloride - Drug Profile
    • neosaxitoxin - Drug Profile
    • oliceridine - Drug Profile
    • oxethazaine - Drug Profile
    • PMZ-2010 - Drug Profile
    • RBM-004 - Drug Profile
    • ropivacaine - Drug Profile
    • ropivacaine ER - Drug Profile
    • SAF-312 - Drug Profile
    • SER-226 - Drug Profile
    • Small Molecule for Post-Operative Pain - Drug Profile
    • sufentanil citrate - Drug Profile
    • tapentadol hydrochloride - Drug Profile
    • tilidine hydrochloride - Drug Profile
    • tramadol hydrochloride - Drug Profile
    • tramadol hydrochloride ER - Drug Profile
    • URB-937 - Drug Profile
    • VVZ-149 - Drug Profile
  • Post-Operative Pain - Dormant Projects
  • Post-Operative Pain - Discontinued Products
  • Post-Operative Pain - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post-Operative Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H1 2017
  • Post-Operative Pain - Pipeline by Adynxx Inc, H1 2017
  • Post-Operative Pain - Pipeline by AngioChem Inc, H1 2017
  • Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
  • Post-Operative Pain - Pipeline by AskAt Inc, H1 2017
  • Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Post-Operative Pain - Pipeline by Camurus AB, H1 2017
  • Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H1 2017
  • Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H1 2017
  • Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H1 2017
  • Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H1 2017
  • Post-Operative Pain - Pipeline by DURECT Corp, H1 2017
  • Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H1 2017
  • Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
  • Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, H1 2017
  • Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2017
  • Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H1 2017
  • Post-Operative Pain - Pipeline by Heron Therapeutics Inc, H1 2017
  • Post-Operative Pain - Pipeline by Immupharma Plc, H1 2017
  • Post-Operative Pain - Pipeline by Innocoll AG, H1 2017
  • Post-Operative Pain - Pipeline by INSYS Therapeutics Inc, H1 2017
  • Post-Operative Pain - Pipeline by iX Biopharma Ltd, H1 2017
  • Post-Operative Pain - Pipeline by Laboratorios Del Dr Esteve SA, H1 2017
  • Post-Operative Pain - Pipeline by Lipocure Ltd, H1 2017
  • Post-Operative Pain - Pipeline by Liquidia Technologies Inc, H1 2017
  • Post-Operative Pain - Pipeline by Medtronic Plc, H1 2017
  • Post-Operative Pain - Pipeline by Novartis AG, H1 2017
  • Post-Operative Pain - Pipeline by Orbis Biosciences Inc, H1 2017
  • Post-Operative Pain - Pipeline by Orion Oyj, H1 2017
  • Post-Operative Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2017
  • Post-Operative Pain - Pipeline by PainReform Ltd, H1 2017
  • Post-Operative Pain - Pipeline by Pharmazz Inc, H1 2017
  • Post-Operative Pain - Pipeline by PhytoHealth Corp, H1 2017
  • Post-Operative Pain - Pipeline by PixarBio Corp, H1 2017
  • Post-Operative Pain - Pipeline by Proteus SA, H1 2017
  • Post-Operative Pain - Pipeline by Recro Pharma Inc, H1 2017
  • Post-Operative Pain - Pipeline by Relmada Therapeutics Inc, H1 2017
  • Post-Operative Pain - Pipeline by Serina Therapeutics Inc, H1 2017
  • Post-Operative Pain - Pipeline by SteadyMed Therapeutics Inc, H1 2017
  • Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, H1 2017
  • Post-Operative Pain - Pipeline by The Medicines Company, H1 2017
  • Post-Operative Pain - Pipeline by Trevena Inc, H1 2017
  • Post-Operative Pain - Dormant Projects, H1 2017
  • Post-Operative Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Post-Operative Pain - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Post-Operative Pain - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Post-Operative Pain, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top